Treatment of basal cell carcinoma with surgical excision and perilesional interferon-α

Journal of Plastic, Reconstructive and Aesthetic Surgery

Volumn 66, Issue 7, 2013, Pages 912-916

  Wettstein, R ^a   Erba, P ^a   Itin, P ^a   Schaefer, D J ^a   Kalbermatten, D F ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Immunomodulation; Non melanoma skin cancer; Recurrence; Safety margin

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SURGERY; CANCER THERAPY; CLINICAL ARTICLE; DRUG SAFETY; EVALUATION AND FOLLOW UP; FROZEN SECTION; HUMAN; OUTCOME ASSESSMENT; PILOT STUDY; PLASTIC SURGERY; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; SURGICAL TECHNIQUE; TUMOR BIOPSY; WOUND DEHISCENCE;

AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; CARCINOMA, BASAL CELL; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRADERMAL; INTERFERON-ALPHA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PILOT PROJECTS; RISK ASSESSMENT; SKIN NEOPLASMS; TREATMENT OUTCOME; WOUND HEALING;

EID: 84878558987     PISSN: 17486815     EISSN: 18780539     Source Type: Journal    
DOI: 10.1016/j.bjps.2013.03.008     Document Type: Article

References (37)

1. A. Sekulic, M.R. Migden, and A.E. Oro Efficacy and safety of vismodegib in advanced basal-cell carcinoma N Engl J Med 366 2012 2171 2179
2. D.D. Hoff Von, P.M. LoRusso, and C.M. Rudin Inhibition of the hedgehog pathway in advanced basal-cell carcinoma N Engl J Med 361 2009 1164 1172
3. M.A. Hofmann, C. Kors, and H. Audring Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma J Immunother 31 2008 520 527
4. S.A. Buechner, M. Wernli, and T. Harr Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide J Clin Invest 100 1997 2691 2696
5. W. Sterry, T. Ruzicka, and E. Herrera Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion Br J Dermatol 147 2002 1227 1236
6. P. Erba, R. Wettstein, S. D'Arpa, and D.F. Kalbermatten Donor site morbidity of the posterior conchal region Dermatol Surg 35 2009 960 964
7. S. Baron, S.K. Tyring, and W.R. Fleischmann The interferons. Mechanisms of action and clinical applications JAMA 266 1991 1375 1383
8. S.B. Tucker, J.W. Polasek, A.J. Perri, and E.A. Goldsmith Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy J Am Acad Dermatol 54 2006 1033 1038
9. L. Edwards, S.B. Tucker, and D. Perednia The effect of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinomas Arch Dermatol 126 1990 1029 1032
10. R. Cornell, H.T. Greenway, and S.B. Tucker Intralesional interferon therapy for basal cell carcinoma J Am Acad Dermatol 23 1990 694 700
11. M.F. Healsmith, J. Berth-Jones, A. Fletcher, and R.A. Graham-Brown Treatment of basal cell carcinoma with intralesional interferon alpha-2b J R Soc Med 84 1991 524 526
12. K. Thestrup-Pedersen, I. Jacobsen, and G. Frentz Intralesional interferon-alpha 2b treatment of basal cell carcinoma Acta Derm Venerol 70 1990 512 514
13. S. Chimenti, K. Peris, and S. Di Cristofaro Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma Dermatology 190 1995 214 217
14. E. Alpsoy, E. Yilmaz, E. Basaran, and S. Yazar Comparison of the effects of intralesional interferon alfa-2a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma J Dermatol 23 1996 394 396
15. B. Doǧan, Y. Harmanyeri, H. Baloǧlu, and I. Oztek Intralesional alfa-2a interferon therapy for basal cell carcinoma Cancer Lett 91 1995 215 219
16. B. Stenquist, A.M. Wennberg, H. Gisselén, and O. Larkö Treatment of aggressive basal cell carcinoma with intralesional interferon: evaluation of efficacy by Mohs surgery J Am Acad Dermatol 27 1992 65 69
17. R. McDonald, and K. Georgouras Treatment of basal cell carcinoma with intralesional interferon alpha: a case report and literature review Australas J Dermatol 33 1992 81 86
18. J.M. Fernández-Vozmediano, and J.C. Armario-Hita Treatment of basal cell carcinoma of the nasal pyramid with intralesional interferon alfa-2b J Drugs Dermatol 9 2010 381 384
19. S.A. Buechner Intralesional interferon alfa-2b in the treatment of basal cell carcinoma. Immunohistochemical study on cellular immune reaction leading to tumor regression J Am Acad Dermatol 24 1991 731 734
20. H.T. Greenway, R. Cornell, and D.J. Tanner Treatment of basal cell carcinoma with intralesional interferon J Am Acad Dermatol 15 1986 437 443
21. L. Anasagasti-Angulo, Y. Garcia-Vega, and S. Barcelona-Perez Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study BMC Cancer 9 2009 262
22. S. Bostanci, P. Kocyigit, and A. Alp Treatment of basal cell carcinoma located in the head and neck region with intralesional interferon alpha-2a: evaluation of long-term follow-up results Clin Drug Investig 25 2005 661 667
23. A. Turan, H. Saricaoglu, and E.B. Baskan Treatment of infiltrating basal cell carcinoma with the combination of intralesional IFN alpha-2b and topical imiquimod 5% cream Int J Dermatol 48 2009 214 215
24. V. Huerva, and I. Mangues Surgery of basal cell carcinoma around the lacrimal canaliculus can be necessary after primary treatment with intralesional interferon alpha 2b Indian J Ophthalmol 56 2008 85 86
25. P. Kumar, S. Watson, and A.N. Brain Incomplete excision of basal cell carcinoma: a prospective multicentre audit Br J Plast Surg 55 2002 616 622
26. R. Wettstein, P. Erba, and J. Farhadi Incomplete excision of basal cell carcinoma in the subunits of the nose Scand J Plast Reconstr Surg Hand Surg 42 2008 92 95
27. T. Dieu, and A.M. Macleod Incomplete excision of basal cell carcinomas: a retrospective audit ANZ J Surg 72 2002 219 221
28. P. Kumar, C.I. Orton, L.J. McWilliam, and S. Watson Incidence of incomplete excision in surgically treated basal cell carcinoma: a retrospective clinical audit Br J Plast Surg 53 2000 563 566
29. P. Erba, J. Farhadi, and R. Wettstein Morphoeic basal cell carcinoma of the face Scand J Plast Reconstr Surg Hand Surg 41 2007 184 188
30. Y. Gulleth, N. Goldberg, R.P. Silverman, and B.R. Gastman What is the best surgical margin for a basal cell carcinoma: a meta-analysis of the literature Plast Reconstr Surg 126 2010 1222 1231
31. R. Wettstein, D.F. Kalbermatten, and U. Rieger High magnification assessment improves complete resection of facial tumors Ann Plast Surg 57 2006 517 520
32. A.E. Macbeth, B.R. Kendall, and A. Smith Calcified subcutaneous nodules: a long-term complication of interferon beta-1a therapy Br J Dermatol 157 2007 624 625
33. N. Ball, B. Cowan, and S. Hashimoto Lobular panniculitis at the site of subcutaneous interferon beta injections for the treatment of multiple sclerosis can histologically mimic pancreatic panniculitis. A study of 12 cases Cutan Pathol 36 2009 331 337
34. L. Sussman, and D. Liggins Incompletely excised basal cell carcinoma: a management dilemma? Aust N Z J Surg 66 1996 276 278
35. T. Wetzig, M. Woitek, and K. Eichhorn Surgical excision of basal cell carcinoma with complete margin control: outcome at 5-year follow-up Dermatology 220 2010 363 369
36. S. Buechner, M. Wernli, and F. Bachmann Intralesional interferon in basal cell carcinoma: how does it work? Recent Results Cancer Res 160 2002 246 250
37. J. Gregorio, S. Meller, and C. Conrad Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons J Exp Med 207 2010 2921 2930